Research Library

As the implementation of Mexico’s historic energy reform gets underway, the debate has tended to overlook a key question at the intersection of technology and the new legislation: How can Mexico create an institutional framework supported by policies, laws and organizations to facilitate technology transfers and foster local innovation? Simply put, how will international oil companies transfer technology to Mexican companies and research facilities?

On Feb. 24, 2015, public finance fellow John Diamond testified on tax reform before U.S. Senate Finance Committee.

The decade 2003-2013 was an exceptional one for Latin America in social terms, but less clearly so in economic terms. Growth slowed down significantly after the exceptional factors that fed the 2003-2007 boom came to an end. The possible unwinding of the super-cycle in commodity prices and, to a lesser extent, of the expansionary monetary policy of the United States, has added new challenges. But the major issue is the need to overcome the poor long-term economic performance that has characterized the region in the post-market reforms period, particularly by adopting active production sector development strategies.

Public finance fellow John Diamond analyzed the proposed Tax Reform Act of 2014 in testimony before the House Subcommittee on Select Revenue Measures on July 30, 2014.

Neal Lane, senior fellow in science and technology policy, testified before the Senate Committee on Commerce, Science and Transportation on July 17, 2014. Lane is co-chair of the American Academy of Arts and Science's project on New Models for U.S. Science and Technology Policy, and his testimony addressed the project's objective of sustaining a long-term, nonpartisan, national focus on science and technology policy issues of vital importance to the country.

Biotechnology scientists must be aware of the broad patent landscape and push for new patent and licensing guidelines, according to a new paper from the Baker Institute.

Cancer drug shortages are almost uniquely associated with generic drugs (small profit margins) and rarely with patented drugs (large profit margins). They are common in the U.S., but uncommon in Europe and elsewhere, where generic drug prices are on average higher than in the U.S. This suggests the main cause of drug shortages is economic.

Every patient with cancer or another life-threatening disease wants the most effective treatment, but drug prices have become staggering. What determines the escalating prices of cancer drugs?

For both generic and patented cancer drugs, the free-market economy has not worked well. Solutions are needed to maintain reasonable drug prices that allow for corporate profits and are affordable to patients and to the U.S. health care system.

In a recent commentary, Baker Institute science and technology policy experts described two international court cases that aimed to define “research” — and that ultimately arrived at two different answers. “What makes this interesting is that the courts’ definition of ‘research’ was based on politics — what the court wanted the end result to be,” said Kirstin Matthews, the institute’s fellow in science and technology policy. To reach a decision prohibiting human embryonic stem cell (hESC) patents, the EU court ruled that “research” occurs in a continuum. To reach a decision supporting federal funding of stem cell research, the U.S. court ruled that “research” involves a specific project.